Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Akebia Therapeutics (AKBA) Net Margin: 2016-2025

Historic Net Margin for Akebia Therapeutics (AKBA) over the last 9 years, with Sep 2025 value amounting to 0.92%.

  • Akebia Therapeutics' Net Margin rose 5446.00% to 0.92% in Q3 2025 from the same period last year, while for Sep 2025 it was -7.07%, marking a year-over-year decrease of 31900.00%. This contributed to the annual value of -43.33% for FY2024, which is 47592.00% up from last year.
  • As of Q3 2025, Akebia Therapeutics' Net Margin stood at 0.92%, which was up 132.41% from 0.40% recorded in Q2 2025.
  • In the past 5 years, Akebia Therapeutics' Net Margin ranged from a high of 23.30% in Q2 2022 and a low of -153.23% during Q1 2022.
  • In the last 3 years, Akebia Therapeutics' Net Margin had a median value of -19.82% in 2023 and averaged -26.12%.
  • Within the past 5 years, the most significant YoY rise in Akebia Therapeutics' Net Margin was 27,760bps (2021), while the steepest drop was 6,468bps (2021).
  • Akebia Therapeutics' Net Margin (Quarterly) stood at -122.10% in 2021, then surged by 11,044bps to -11.66% in 2022, then soared by 1,118bps to -0.48% in 2023, then tumbled by 4,857bps to -49.04% in 2024, then soared by 5,446bps to 0.92% in 2025.
  • Its last three reported values are 0.92% in Q3 2025, 0.40% for Q2 2025, and 10.66% during Q1 2025.